STOCK TITAN

Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will participate in two upcoming investor conferences in September 2022. The Citi's 17th Annual BioPharma Conference is scheduled for September 7, 2022, at 1:00 p.m. ET. The Wells Fargo Healthcare Conference will follow on September 8, 2022, at 11:00 a.m. ET. Audio webcasts of both presentations will be available on the Jazz Pharmaceuticals website and will be archived for 30 days.

Positive
  • None.
Negative
  • None.

DUBLIN, Aug. 31, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming investor conferences:

Citi's 17th Annual BioPharma Conference on Wednesday, September 7, 2022  

  • The presentation is scheduled for 1:00 p.m. ET / 6:00 p.m. IST.

2022 Wells Fargo Healthcare Conference on Thursday, September 8, 2022

  • The presentation is scheduled for 11:00 a.m. ET / 4:00 p.m. IST.

Audio webcasts of the presentations will be available via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Replays of the webcasts will be archived on the website for 30 days following the conferences.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.

Contacts:

Investors:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717

Media:

Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948

 

Jazz Pharmaceuticals Logo (PRNewsFoto/Jazz Pharmaceuticals plc) (PRNewsFoto/Jazz Pharmaceuticals plc)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-participate-in-upcoming-september-investor-conferences-301615817.html

SOURCE Jazz Pharmaceuticals plc

FAQ

What dates will Jazz Pharmaceuticals participate in investor conferences in September 2022?

Jazz Pharmaceuticals will participate in two investor conferences: Citi's 17th Annual BioPharma Conference on September 7, 2022, and the Wells Fargo Healthcare Conference on September 8, 2022.

What time is Jazz Pharmaceuticals' presentation at Citi's BioPharma Conference?

Jazz Pharmaceuticals' presentation at Citi's BioPharma Conference is scheduled for 1:00 p.m. ET on September 7, 2022.

Where can I listen to Jazz Pharmaceuticals' conference presentations?

You can listen to Jazz Pharmaceuticals' conference presentations via audio webcasts available on their website. Replays will be archived for 30 days.

What is the stock symbol for Jazz Pharmaceuticals?

The stock symbol for Jazz Pharmaceuticals is JAZZ.

What is the significance of the upcoming investor conferences for Jazz Pharmaceuticals?

The upcoming investor conferences provide Jazz Pharmaceuticals with a platform to share insights on their innovative therapies and engage with investors.

Jazz Pharmaceuticals, Inc.

NASDAQ:JAZZ

JAZZ Rankings

JAZZ Latest News

JAZZ Stock Data

7.65B
58.63M
2.94%
98.78%
5.94%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
DUBLIN